- 27Oct, 2025
US infections caused by NDM-producing carbapenem-resistant Enterobacterales (NDM-CRE) increased by more than 460% from 2019 to 2023, according to a Centers for Disease Control and Prevention (CDC) analysis published in Annals of Internal Medicine. CDC cautions that this surge could raise overall carbapenem-resistant Enterobacterales (CRE) infections [...]
Podcast interview, CareTalk: Healthcare. Unfiltered. Reversing the Rapid Rise of Antibiotic Resistance
Reversing the Rapid Rise of Antibiotic Resistance. Greg Mario joins David E. Williams to discuss the real and potentially imminent dangers of antibiotic-resistant infections and the new technologies being developed to combat this growing threat.
The Path to New Solutions in the Fight Against Antimicrobial Resistance
Antimicrobial resistance (AMR) is not a new phenomenon; it has been a persistent challenge since the discovery of antibiotics. TAXIS Pharmaceuticals is at the forefront of addressing antimicrobial resistance, developing innovative antimicrobial solutions.
- 7Nov, 2024
On July 25, House Budget Committee bipartisan roundtable entitled, “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance (AMR) and the Broken Antibiotic Development Pipeline.”
- 6Sep, 2024
Antibiotic resistance – or antimicrobial resistance (AMR) – has been making headlines for decades. At TAXIS Pharmaceuticals, we have been working since 2009 on the development of compounds that combat antimicrobial resistance.
- 14Oct, 2024
TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant to Advance Research and Development of Combination Therapy to Combat Antibiotic-Resistant Pneumonia. Originally published in NORTH BRUNSWICK, N.J., May 1, 2024 /PRNewswire-PRWeb/
